The pulmonary vasodilator properties of potassium channel opening drugs

Wanstall J.C. (1996) The pulmonary vasodilator properties of potassium channel opening drugs. General Pharmacology, 27 4: 599-605. doi:10.1016/0306-3623(95)02044-6


Author Wanstall J.C.
Title The pulmonary vasodilator properties of potassium channel opening drugs
Journal name General Pharmacology   Check publisher's open access policy
ISSN 0306-3623
Publication date 1996-01-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/0306-3623(95)02044-6
Volume 27
Issue 4
Start page 599
End page 605
Total pages 7
Publisher Elsevier Inc.
Language eng
Subject 3004 Pharmacology
Abstract 1. This article reviews the effects of potassium channel opening drugs (KCOs) on blood vessels of the pulmonary circulation. KCOs are effective pulmonary vasodilators in vitro (isolated arteries and perfused lungs) and in vivo in a variety of animal species. They prevent or reverse pulmonary vasoconstriction/contraction induced by a range of vasoconstrictor spasmogens or by alveolar hypoxia. 2. The pulmonary vasorelaxant effects of the KCO drugs are blocked by glibenclamide, do not depend on the endothelium, are dependent on the vasoconstrictor spasmogen used to contract the preparations and are enhanced in preparations taken from pulmonary hypertensive rats. 3. Selectivity for pulmonary compared with systemic vessels is seen in vessels from pulmonary hypertensive rats but not in the absence of pulmonary hypertension. 4. The pulmonary vasodilatation that is induced by (a) endothelium derived hyperpolarising factor, (b) endothelin, (c) increased pulmonary blood flow or (d) prolonged, severe hypoxia is probably due to potassium efflux through the same population of potassium channels as chose on which the KCOs act. 5. Acute hypoxic pulmonary vasoconstriction, and also the depolarisation seen in arteries from chronically hypoxic rats, each involve inhibition of potassium efflux through glibenclamide insensitive potassium channels. 6. It is suggested that the KCOs warrant investigation as possible therapeutic agents in the treatment of pulmonary hypertension.
Keyword Hypoxia
Potassium channel openers
Pulmonary hypertension
Pulmonary vasodilators
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collection: Scopus Import
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 23 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 26 Jul 2016, 14:17:59 EST by System User